Sarepta Therapeutics (NASDAQ:SRPT) Raised to Hold at Wall Street Zen

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research firms also recently issued reports on SRPT. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research note on Tuesday, January 27th. Royal Bank Of Canada upped their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 8th. Wells Fargo & Company lowered their price target on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Finally, Robert W. Baird decreased their price objective on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $33.56.

Sarepta Therapeutics Stock Down 4.0%

Sarepta Therapeutics stock opened at $16.76 on Friday. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $108.48. The firm’s fifty day simple moving average is $20.43 and its 200-day simple moving average is $20.21. The company has a market capitalization of $1.76 billion, a P/E ratio of -1.99, a P/E/G ratio of 0.44 and a beta of 0.39.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The business had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative return on equity of 49.42% and a negative net margin of 38.34%.The company’s quarterly revenue was down 32.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.90 earnings per share. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. This represents a 6.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Sarepta Therapeutics by 9.2% in the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock valued at $254,167,000 after buying an additional 993,283 shares during the period. AQR Capital Management LLC raised its holdings in Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares in the last quarter. Erste Asset Management GmbH lifted its position in shares of Sarepta Therapeutics by 1.6% in the 4th quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock worth $58,727,000 after acquiring an additional 43,000 shares during the period. Aberdeen Group plc lifted its position in shares of Sarepta Therapeutics by 13.6% in the 4th quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock worth $48,454,000 after acquiring an additional 268,829 shares during the period. Finally, First Trust Advisors LP grew its holdings in shares of Sarepta Therapeutics by 2.7% during the 4th quarter. First Trust Advisors LP now owns 1,992,577 shares of the biotechnology company’s stock worth $42,880,000 after purchasing an additional 52,796 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.